Last 7 days
-1.1%
Last 30 days
1.1%
Last 90 days
5.5%
Trailing 12 Months
33.6%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
SYK | 110.8B | 19.0B | -8.78% | 16.43% | 46.98 | 6.01 | 8.73% | 30.37% |
ISRG | 107.5B | 6.4B | 4.05% | 37.44% | 81.96 | 16.72 | 8.89% | -20.19% |
BSX | 74.1B | 13.0B | -0.08% | 27.20% | 106.12 | 5.84 | 7.26% | -32.95% |
BDX | 71.3B | 18.8B | -6.73% | -3.13% | 44.09 | 3.79 | -1.96% | -15.83% |
EW | 49.7B | 5.5B | -6.18% | -16.80% | 33.38 | 9.03 | 2.68% | -3.23% |
MID-CAP | ||||||||
SWAV | 7.2T | 557.2M | -1.64% | 66.40% | 82.2K | 16.8K | 86.42% | 730.06% |
PEN | 11.7B | 884.6M | 7.85% | 115.97% | 1.8K | 13.2 | 13.08% | 200.12% |
GMED | 5.9B | 1.1B | -8.20% | -19.98% | 34.14 | 5.75 | 11.20% | 53.04% |
IRTC | 3.6B | 430.0M | -11.89% | -12.63% | -34.73 | 8.45 | 26.13% | 15.73% |
TNDM | 1.7B | 794.7M | -29.15% | -60.56% | -8.43 | 2.16 | 7.73% | -3556.34% |
SMALL-CAP | ||||||||
ATEC | 1.6B | 389.0M | -3.76% | 82.19% | -10.63 | 4.18 | 44.08% | 6.96% |
SILK | 1.2B | 150.7M | -30.80% | 0.49% | -21.65 | 7.87 | 40.31% | 1.80% |
AVNS | 1.1B | 814.3M | -20.14% | -16.22% | 24.47 | 1.34 | 6.96% | 121.89% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 4.2% | 1,129 | 1,084 | 1,026 | 993 | 953 |
Gross Profit | 3.5% | 595 | 575 | 540 | 506 | - |
Operating Expenses | 2.8% | 455 | 443 | 430 | 425 | - |
S&GA Expenses | 3.9% | 371 | 357 | 341 | 340 | - |
R&D Expenses | 5.9% | 48.00 | 45.00 | 45.00 | 47.00 | - |
EBITDA | 4.8% | 218 | 208 | 187 | 168 | - |
EBITDA Margin | 0.6% | 0.19* | 0.19* | 0.18* | 0.17* | - |
Earnings Before Taxes | 9.6% | 124 | 113 | 92.00 | 64.00 | - |
EBT Margin | 5.1% | 0.11* | 0.10* | 0.09* | 0.06* | - |
Interest Expenses | - | 6.00 | - | - | - | - |
Net Income | 11.3% | 96.00 | 86.00 | 68.00 | 43.00 | - |
Net Income Margin | 6.8% | 0.08* | 0.08* | 0.07* | 0.04* | - |
Free Cahsflow | 10.1% | 128 | 116 | 88.00 | 76.00 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | 3.0% | 1,935 | 1,878 | 1,865 | 1,821 | 1,860 |
Current Assets | 9.0% | 770 | 706 | 716 | 688 | 756 |
Cash Equivalents | 27.0% | 284 | 224 | 241 | 215 | 259 |
Inventory | 1.4% | 259 | 256 | 255 | 278 | 293 |
Net PPE | -0.7% | 311 | 313 | 308 | 288 | 258 |
Goodwill | 0.0% | 466 | 466 | 465 | 466 | 467 |
Current Liabilities | 11.0% | 252 | 227 | 262 | 180 | 442 |
LT Debt, Current | 18.4% | 12.00 | 10.00 | 58.00 | 7.00 | 214 |
LT Debt, Non Current | -0.4% | 754 | 757 | 760 | 763 | 559 |
Shareholder's Equity | 5.4% | 818 | 776 | 729 | 770 | 749 |
Retained Earnings | 13.1% | 253 | 224 | 204 | 222 | 202 |
Additional Paid-In Capital | 1.2% | 595 | 587 | 564 | 580 | 572 |
Shares Outstanding | 0.0% | 50.00 | 50.00 | 51.00 | 51.00 | 51.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | 4.4% | 273 | 261 | 260 | 216 | 172 |
Share Based Compensation | 8.3% | 26.00 | 24.00 | 23.00 | 23.00 | 24.00 |
Cashflow From Investing | 10.3% | -143 | -160 | -139 | -128 | -86.34 |
Cashflow From Financing | 6.7% | -100 | -107 | -59.88 | -37.51 | -15.75 |
Buy Backs | -25.0% | 75.00 | 100 | 100 | 0.00 | - |
80.4%
53.1%
28.1%
Y-axis is the maximum loss one would have experienced if Haemonetics was unfortunately bought at previous high price.
7.1%
16.8%
-1.7%
-8.3%
FIve years rolling returns for Haemonetics.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-23 | ROYCE & ASSOCIATES LP | added | 2.22 | 4,898,060 | 69,820,600 | 0.70% |
2023-05-23 | Toroso Investments, LLC | added | 10.49 | 72,000 | 516,000 | 0.01% |
2023-05-22 | American Trust | sold off | -100 | -207,636 | - | -% |
2023-05-22 | AMERIPRISE FINANCIAL INC | added | 3.22 | 3,014,030 | 38,085,000 | 0.01% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | added | 21.13 | 1,111,000 | 5,161,000 | 0.01% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | unchanged | - | 210,000 | 8,022,000 | 0.01% |
2023-05-18 | JPMORGAN CHASE & CO | added | 16.11 | 2,672,000 | 14,721,000 | -% |
2023-05-17 | Advisory Services Network, LLC | added | 2.59 | 1,687 | 22,922 | -% |
2023-05-17 | VIRGINIA RETIREMENT SYSTEMS ET AL | added | 76.53 | 635,151 | 1,360,640 | 0.01% |
2023-05-17 | Thrivent Financial for Lutherans | reduced | -1.23 | 42,000 | 1,102,000 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 13, 2023 | capital research global investors | 11.8% | 5,956,064 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 10.36% | 5,242,836 | SC 13G/A | |
Feb 06, 2023 | wellington management group llp | 7.97% | 4,034,753 | SC 13G/A | |
Jan 26, 2023 | blackrock inc. | 11.7% | 5,898,620 | SC 13G/A | |
Jan 20, 2023 | blackrock inc. | 11.7% | 5,898,620 | SC 13G/A | |
Apr 08, 2022 | capital research global investors | 10.7% | 5,452,006 | SC 13G | |
Feb 14, 2022 | neuberger berman group llc | 7.59% | 3,876,521 | SC 13G/A | |
Feb 11, 2022 | capital research global investors | 4.0% | 2,049,133 | SC 13G/A | |
Feb 10, 2022 | vanguard group inc | 9.55% | 4,880,936 | SC 13G/A | |
Feb 10, 2022 | wellington management group llp | 10.83% | 5,537,538 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
May 22, 2023 | 10-K | Annual Report | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 17, 2023 | 4 | Insider Trading | |
May 17, 2023 | 4 | Insider Trading | |
May 17, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-05-18 | Miller Laurie A. | sold (taxes) | -7,500 | 83.34 | -90.00 | svp, human resources |
2023-05-18 | Basil Michelle L | sold (taxes) | -295,107 | 83.34 | -3,541 | evp and general counsel |
2023-05-18 | Strong Stewart W | sold (taxes) | -90,590 | 83.34 | -1,087 | president, global hospital |
2023-05-18 | Simon, Christopher | sold (taxes) | -319,942 | 83.34 | -3,839 | president & ceo |
2023-05-18 | Lingamneni Anila | sold (taxes) | -115,426 | 83.34 | -1,385 | evp, chief technology officer |
2023-05-18 | Llorens Josep | sold (taxes) | -118,593 | 83.34 | -1,423 | evp, global manufacturing |
2023-05-16 | Basil Michelle L | sold (taxes) | -39,787 | 89.21 | -446 | evp and general counsel |
2023-05-16 | Simon, Christopher | sold (taxes) | -141,487 | 89.21 | -1,586 | president & ceo |
2023-05-16 | Lingamneni Anila | sold (taxes) | -28,368 | 89.21 | -318 | evp, chief technology officer |
2023-05-16 | Strong Stewart W | sold (taxes) | -22,302 | 89.21 | -250 | president, global hospital |
CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Apr. 01, 2023 | Apr. 02, 2022 | Apr. 03, 2021 | |
Income Statement [Abstract] | |||
Net revenues | $ 1,168,660 | $ 993,196 | $ 870,463 |
Cost of goods sold | 553,563 | 487,694 | 472,625 |
Gross profit | 615,097 | 505,502 | 397,838 |
Operating expenses: | |||
Research and development | 50,131 | 46,801 | 32,857 |
Selling, general and administrative | 376,675 | 340,140 | 275,216 |
Amortization of acquired intangible assets | 32,640 | 47,414 | 32,830 |
Gains on divestitures and sale of assets | (382) | (9,603) | (32,812) |
Total operating expenses | 459,064 | 424,752 | 308,091 |
Operating income | 156,033 | 80,750 | 89,747 |
Interest and other expense, net | (14,630) | (17,121) | (16,834) |
Income before provision (benefit) for income taxes | 141,403 | 63,629 | 72,913 |
Provision (benefit) for income taxes | 26,002 | 20,254 | (6,556) |
Net income | $ 115,401 | $ 43,375 | $ 79,469 |
Net income per share - basic (in dollars per share) | $ 2.27 | $ 0.85 | $ 1.57 |
Net income per share - diluted (in dollars per share) | $ 2.24 | $ 0.84 | $ 1.55 |
Weighted average shares outstanding | |||
Basic (in shares) | 50,783 | 51,047 | 50,688 |
Diluted (in shares) | 51,420 | 51,353 | 51,292 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Apr. 01, 2023 | Apr. 02, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 284,466 | $ 259,496 |
Accounts receivable, less allowance for credit losses of $4,932 at April 1, 2023 and $2,475 at April 2, 2022 | 179,142 | 159,376 |
Inventories, net | 259,379 | 293,027 |
Prepaid expenses and other current assets | 46,735 | 44,132 |
Total current assets | 769,722 | 756,031 |
Property, plant and equipment, net | 310,885 | 258,482 |
Intangible assets, less accumulated amortization of $417,422 at April 1, 2023 and $376,552 at April 2, 2022 | 275,771 | 310,261 |
Goodwill | 466,231 | 467,287 |
Deferred tax asset | 5,241 | 4,468 |
Other long-term assets | 106,975 | 63,205 |
Total assets | 1,934,825 | 1,859,734 |
Current liabilities: | ||
Notes payable and current maturities of long-term debt | 11,784 | 214,148 |
Accounts payable | 63,929 | 58,371 |
Accrued payroll and related costs | 64,475 | 48,540 |
Other current liabilities | 111,628 | 121,207 |
Total current liabilities | 251,816 | 442,266 |
Long-term debt, net of current maturities | 754,102 | 559,441 |
Deferred tax liability | 36,195 | 28,727 |
Other long-term liabilities | 74,715 | 79,876 |
Stockholders’ equity: | ||
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 50,448,519 shares at April 1, 2023 and 51,124,240 shares at April 2, 2022 | 504 | 511 |
Additional paid-in capital | 594,706 | 572,476 |
Retained earnings | 253,168 | 202,391 |
Accumulated other comprehensive loss | (30,381) | (25,954) |
Total stockholders’ equity | 817,997 | 749,424 |
Total liabilities and stockholders’ equity | $ 1,934,825 | $ 1,859,734 |